FDA Readies New Guidance and User Fee Program for Biosimilars: Drug interchangeability and user fees are contentious issues the FDA must resolve. Is the FDA up to the task?

Ítems similars

• FDA Guidance on Biosimilar Interchangeability Elicits Diverse Views: Current and Potential Marketers Complain About Too-High Hurdles
  per: Barlas, Stephen
  Publicat: (2017)
• FDA Pleases No One With Final Guidance On Naming of Biologicals and Biosimilars
  per: Barlas, Stephen
  Publicat: (2017)
• Congress Readying User Fee Program for OTC Products: Money Needed to Dig FDA Out of Its Review Ditch
  per: Barlas, Stephen
  Publicat: (2018)
• Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry
  per: Koyfman, Hannah
  Publicat: (2013)
• FDA User Fees Gain Momentum
  per: Punzo, Christine
  Publicat: (1992)